Warnex Inc.

Warnex Inc.

June 15, 2006 10:41 ET

Warnex obtains interim court order in dispute with OPMedic

LAVAL, QC, June 15 - Warnex Inc. (TSX:WNX) today announced that
following the institution of a motion for the issuance of a provisional
injunction, an interlocutory injunction as well as a permanent injunction
against Groupe OPMedic Inc. ("OPMedic"), the Superior Court of Quebec granted
yesterday a safeguard order which requires OPMedic to refer exclusively to
Warnex all blood samples collected for the purpose of prenatal screening.

The order also provides for the smooth transition of tests already
undertaken under OPMedic's competing test. The effect of this judgment will be
to maintain the status quo of the commercial relationship which has existed
between OPMedic and Warnex since June 2004. The order is valid until October
13, 2006, date on which the parties are scheduled to return before the
Superior Court.

This follows a previously announced dispute with OPMedic's Procrea
Cliniques division ("Procrea"), after Warnex had been advised by OPMedic that
Procrea would offer a prenatal test which competes with Warnex's Prenatest®
prenatal screening test and that it would perform in-house the related
analysis of the blood samples, as of June 2006.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
DNA-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

Warnex is a trademark and Prenatest is a registered trademark of Warnex Inc., Laval, Quebec.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, manufacturing and laboratory facilities, suppliers,
key employees, key customers, financial resources and credit risk, government
regulations, foreign currency risk and volatility of share price, and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to the
heading Risks and Uncertainties in the Management's Discussion and Analysis
for the first quarter ended March 31, 2006, which can be found at
www.sedar.com. Consequently, actual results may differ materially from the
anticipated results expressed in these forward-looking statements.

Contact Information